Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: A post hoc pooled analysis of 2 randomized, placebo-controlled, Phase 3 trials

Dermatologic Surgery

Volumn 40, Issue 7, 2014, Pages 776-785

  Jones, Derek ^a   Carruthers, Jean ^b   Narins, Rhoda S ^c   Coleman III, William P ^d   Harrington, Laura ^e   Brandt, Fredric S ^f   Cohen, Joel L ^g  

^a Skin Care and Laser Physicians of Beverly Hills   (United States)

^b Carruthers Clinical Research   (Canada)

^c Dermatology Surgery and Laser Center   (United States)

^d Coleman Cosmetic Dermatologic Surgery Center ^*  (United States)

^e Dermatology Research Institute ^*

^f Dermatology Research Institute   (United States)

^g AboutSkin Dermatology and DermSurgery PC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; ARTICLE; BODY MASS; CANADA; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; GLABELLAR FROWN LINE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE DISEASE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNITED STATES;

ADULT; BOTULINUM TOXINS, TYPE A; FEMALE; FOREHEAD; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; SKIN AGING; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904725584     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/dsu.0000000000000001     Document Type: Article

References (24)

1. Carruthers A, Carruthers J, Coleman WP III, Donofrio L, et al. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg 2013;39:551-8.
2. Hanke CW, Narins RS, Brandt F, Cohen JL, et al. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg 2013;39:891-9.
3. Imhof M, Kühne U. A phase III study of incobotulinumtoxinA in the treatment of glabellar frown lines. J Clin Aesthet Dermatol 2011;4:28-34.
4. Lee JH, Park JH, Lee SK, Han KH, et al. The efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side by side comparison with onabotulinum toxin A. J Dermatolog Treat 2014;25:326-30.
5. Oliveira De Morais O, Matos Reis-Filho E, Vilela Pereira L, Martins Gomes C, et al. Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot study. J Drugs Dermatol 2012;11:216-9.
6. Prager W, Bee EK, Havermann I, Zschocke I. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-Arm, prospective clinical study. Clin Interv Aging 2013;8:449-56.
7. Prager W, Wissmüller E, Kollhorst B, Williams S, et al. Comparison of two botulinum toxin type A preparations for treating crow's feet: a splitface, double-blind, proof-of-concept study. Dermatol Surg 2010;36:2155-60.
8. Sattler G, Callander MJ, Grablowitz D, Walker T, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 2010;36:2146-54.
9. Benecke R, Jost WH, Kanovsky P, Ruzicka E, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005;64:1949-51.
10. Roggenkämper P, Jost WH, Bihari K, Comes G, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006;113:303-12.
11. Kanovsky P, Slawek J, Denes Z, Platz T, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 2009;35:259-65.
12. Baumann L, Brandt FS, Kane MA, Donofrio LM. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J 2009;29:S57-65.
13. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebocontrolled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009;35:1893-901.
14. Carruthers JA, Lowe NJ, Menter MA, Gibson J, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002;46:840-9.
15. Carruthers JD, Lowe NJ, Menter MA, Gibson J, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003;112:1089-98.
16. Pinto VF. Non-inferiority versus equivalence clinical trials in assessing biological products. Sao Paulo Med J 2011;129:183-4.
17. Rappl T, Parvizi D, Friedl H, Wiedner M, et al. Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clin Cosmet Investig Dermatol 2013;6:211-9.
18. Glogau R, Kane M, Beddingfield F, Somogyi C, et al. OnabotulinumtoxinA: a meta-Analysis of duration of effect in the treatment of glabellar lines. Dermatol Surg 2012;38:1794-803.
19. Kane M, Donofrio L, Ascher B, Hexsel D, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol 2010;9:s7-22.
20. Raspaldo H, Baspeyras M, Bellity P, Dallara JM, et al. Upper- and midface anti-Aging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus-part 1. J Cosmet Dermatol 2011;10:36-50.
21. Kane MA, Brandt F, Rohrich RJ, Narins RS, et al. Evaluation of variable-dose treatment with a new U. S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009;124:1619-29.
22. Benecke R, Hauschke D. IncobotulinumtoxinA demonstrated equivalent efficacy to onabotulinumtoxinA in the treatment of cervical dystonia. Botulinum J 2013;2:217.
23. Roggenkämper P, Hauschke D. IncobotulinumtoxinA demonstrated equal efficacy to onabotulinumtoxinA in the treatment of blepharospasm. Botulinum J 2013;2:329.
24. Prager W, Huber-Vorländer J, Taufig AZ, Imhof M, et al. Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice. Clin Cosmet Investig Dermatol 2012;5:53-8.